SPC
INDP icon

Sigma Planning Corp’s Indaptus Therapeutics INDP Stock Holding History

Sigma Planning Corp’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8
Closed -$80K – 1031
2019
Q2 		$80K Sell
8
-3
-27% -$37.8K ﹤0.01% 964
2019
Q1 		$183K Buy
+11
New +$193K 0.01% 867

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Sigma Planning Corp's INDP Position: Q3 2019 in Review

Sigma Planning Corp sold out of Indaptus Therapeutics (INDP) in Q3 2019, closing a stake of 8 shares — an estimated $80K sold.

Sigma Planning Corp first reported a position in INDP in Q1 2019 and held it in 2 quarters. The position peaked at $183K in Q1 2019. 33 funds tracked by Wall St. Rank hold INDP as of Q3 2019.

  • Sigma Planning Corp reported no remaining Indaptus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Sigma Planning Corp sold 8 Indaptus Therapeutics shares in Q3 2019, an estimated $80K.
  • Sigma Planning Corp first reported a position in Indaptus Therapeutics in Q1 2019 and held it in 2 quarters.
  • Sigma Planning Corp's Indaptus Therapeutics position peaked at $183K in Q1 2019.
  • 33 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2019.

Based on Sigma Planning Corp's 13F filing for Q3 2019, filed 1 Nov 2019.